Véronique Hentgen

Dr. Véronique Hentgen

Department of General Pediatrics, CEREMAIA, CH Versailles, 78157 Le Chesnay, France

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
VHVéronique Hentgen
Véronique Hentgen
GGGilles Grateau
Gilles Grateau
IKIsabelle Kone-Paut
Isabelle Kone-Paut
ALAvi Livneh
Avi Livneh
SPShai Padeh
Shai Padeh
EBEldad Ben-Chetrit
Eldad Ben-Chetrit

1 August 2020 in Best Practice & Research Clinical Rheumatology
Verified
Journal Article
Closed access
SGSophie Anne Georgin-Lavialle
Sophie Anne Georgin-Lavialle
SDStéphanie Ducharme-Benard
Stéphanie Ducharme-Benard
GSGuillaume Sarrabay
Guillaume Sarrabay
LSLéa Savey
Léa Savey
GGGilles Grateau
Gilles Grateau
VHVéronique Hentgen
Véronique Hentgen

28 May 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
VHVéronique Hentgen
Véronique Hentgen
CVCaroline Vinit
Caroline Vinit
AFAntoine Fayand
Antoine Fayand
SGSophie Georgin-Lavialle
Sophie Georgin-Lavialle
Purpose: Familial Mediterranean fever (FMF) is the most common monogenic auto-inflammatory disease characterized by recurrent attacks of fever and serositis. It is associated with mutation in pyrin inflammasome leading to interleukin-1 (IL-1) over secretion. Although colchicine is the first line treatment in FMF, 5–10% of patients are reported in literature as non-responders. Colchicine is not always well-tolerated due either to its direct toxicity or to co-morbidities that preclude the administration of its proper dosage. For these patients an alternative or additional treatment to colchicine is necessary. This literature review reports the published data regarding the use of IL-1 inhibitors in Familial Mediterranean Fever. Results: There is no uniform definition of colchicine resistance, but the different studies of treatment with IL-1 inhibitors provide evidence of IL-1 pathogenic role in colchicine-resistant FMF. IL-1 inhibition is an efficacious option for controlling and preventing flares –at least at the short term- in FMF patients who are insufficiently controlled with colchicine alone. Although canakinumab is the only approved drug in Europe for colchicine resistant FMF treatment, experience with anakinra is also substantial. In the absence of comparative studies both treatments seem to be an equal option for the management of these patients. Overall the safety profile of IL-1 inhibitors seems not different in FMF patients than in the other diseases and can be considered as globally safe. The main side effects are local injection site reactions and infections. Conclusion: IL-1 inhibitors have the potential to improve patient outcome even in FMF patients with co-morbidities or severe complications in whom inflammation control is difficult to achieve with colchicine alone. Nevertheless, current data are limited and further evaluation of long-term efficacy and safety of IL-1 inhibitors are necessary, in order to provide robust evidence in this domain.

18 March 2013 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
VHVéronique Hentgen
Véronique Hentgen
GGGilles Grateau
Gilles Grateau
KSKatia Stankovic‐Stojanovic
Katia Stankovic‐Stojanovic
SASerge Amselem
Serge Amselem
IJIsabelle Jéru
Isabelle Jéru
Objective: Familial Mediterranean fever (FMF) is an autosomal‐recessive autoinflammatory disease due to mutations in MEFV. Descriptions of disease manifestations among patients carrying a single mutated MEFV allele are becoming more frequent, although no data are available on the long‐term outcome. We undertook this study to assess the accuracy of clinical diagnosis in children carrying a single mutated MEFV allele with symptoms of recurrent autoinflammatory disorder.Methods: We performed a retrospective single‐center study of 33 patients with autoinflammatory disorders age <6 years at disease onset with 1 mutated MEFV allele. The phenotype of the patients was investigated in detail, and the clinical picture and outcome of 18 patients with an initial FMF diagnosis according to current clinical criteria were compared to those of 25 homozygous or compound heterozygous FMF patients.Results: No major differences in presenting signs or initial response to colchicine were observed between patient groups. During followup, heterozygotes had a milder disease course compared to homozygotes and were less prone than homozygotes to experience new clinical signs of FMF. At puberty, clinical signs of FMF completely disappeared in 5 of 18 heterozygotes, allowing them to discontinue colchicine without recurrence of symptoms or increases in inflammatory marker levels.Conclusion: Our data suggest that the clinical diagnosis of FMF in very young heterozygous children should be made with caution. At this young age they can present with an FMF‐like disease—similar to that seen in patients carrying 2 mutated alleles—that is not necessarily predictive of life‐long illness.

14 June 2015 in Rheumatology
Verified
Journal Article
Closed access
PDF file
CGClaire Grimwood
Claire Grimwood
VDVéronique Despert
Véronique Despert
IJIsabelle Jeru
Isabelle Jeru
VHVéronique Hentgen
Véronique Hentgen

9 August 2018 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
CGClaire Grimwood
Claire Grimwood
IKisabelle Koné-Paut
isabelle Koné-Paut
MPMaryam Piram
Maryam Piram
LRLinda Rossi-Semerano
Linda Rossi-Semerano
VHVéronique Hentgen
Véronique Hentgen
Conventionally, PFAPA syndrome is considered as a benign disease compared to other recurrent fevers because it completely passes before adulthood. However, in our clinical practice, fever episodes have a huge impact on daily activities. Observational cohort study using the Pediatric Quality of Life Inventory (PedsQL™ 4.0) Generic Core and Fatigue Scales. PedsQL™ uses a modular approach to measure the HRQOL in children with acute and chronic health conditions. We used pediatric FMF patients as the control group. We included 33 children with PFAPA and compared them to 27 FMF patients matched for age: preschool-age children (2 to 7 years) and school-age children and youths (8 to18 years). PedsQL™ self-reported scores of children with PFAPA were systematically lower than those of FMF peers for general quality of life and physical and psychosocial functioning (significant only in the preschool-age group). PedsQL™ self-reported fatigue scores of children with PFAPA were significantly lower than those of FMF peers for both preschoolers and school-age children and youths. Parent proxy-reports were not significantly different, even though scores were systematically lower for the parents of PFAPA children. Our study demonstrates, for the first time, that the wellbeing of PFAPA children is poor, with a major impact on psychosocial functioning and increased fatigue. The quality of life of PFAPA children appears to be even lower than that of FMF patients, for whom a lower than normal HRQOL has already been demonstrated.